Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.

NCT07011329 | Active Not Recruiting DMC

• 1 other identifier: LLHBCH2023YN-019
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to examine the potential impact of the treatment before, during, and/or after radiotherapy on the brain in patients with nasopharyngeal carcinoma (NPC) using Multiplex (MTP) MR imaging sequence, which generate multiple contrasts with one-time scan. We aimed to investigate the altered MTP parameters and their correlation with clinical cognitive scores before and after the treatment.

Conditions

Nasopharyngeal Carcinoma (NPC)

Keywords

npc; MTP; Cognitive decline

Outcome Measures

Primary Outcomes (1)

• volume

  the brain volume changes after treatment in NPC patients

  3 months

Study Arms (1)

before(pre-) and after (post-) treatment groups

The pre-treatment group refers to before treatment, while the post-treatment group refers to after treatment.

Radiation: Changes in the brain MTP parameters after radiotherapy

Interventions

Changes in the brain MTP parameters after radiotherapy RADIATION

Our study explores the changes in brain MTP parameters and their correlation with clinical cognitive scores before and after chemotherapy and/or radiotherapy in patients with NPC. We investigates MRI-derived multiparametric imaging biomarkers (MTP) as predictive biomarkers for chemotherapy/radiotherapy-induced cognitive decline in nasopharyngeal carcinoma, aiming to optimize neurotoxicity risk stratification and guide personalized neuroprotective interventions in precision oncology.

before(pre-) and after (post-) treatment groups

Eligibility Criteria

• Age: 30 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients

You may qualify if:

• pathological evidence of NPC (stages III-IV at diagnosis according to the 8th edition of the UICC/AJCC staging system for NPC)
• right-handed
• prepared to receive treatments
• prepared to receive the Montreal Cognitive Assessment (MoCA)

You may not qualify if:

• brain invasion
• brain tumor or atrophy, neural-associated diseases, a history of brain surgery
• any current medications that may affect cognitive function
• inability to attend MRI scanning

Sponsors & Collaborators

• Hubei Cancer Hospital: lead

Study Sites (1)

Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430079, China

Location

Related Links

• United Imaging Healthcare Official Website of uAiFI Techology including brain analysis based on MTP
• United Imaging Healthcare Official Chinese Website of uAiFI Techology including brain analysis, which used brainTool software based on MTP

MeSH Terms

Conditions

Nasopharyngeal Carcinoma; Niemann-Pick Disease, Type A; Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Nasopharyngeal Neoplasms; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Niemann-Pick Diseases; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Lymphatic Diseases; Hemic and Lymphatic Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Lipidoses; Lipid Metabolism, Inborn Errors; Lysosomal Storage Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Lipid Metabolism Disorders; Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Study Officials

• Zilong Yuan, MD

  Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology

  STUDY DIRECTOR

• Dan Liu, MD

  Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: physician-in-charge

Study Record Dates

• First Submitted: May 30, 2025
• First Posted: June 8, 2025
• Study Start: April 1, 2023
• Primary Completion: December 31, 2025
• Study Completion (Estimated): December 31, 2027
• Last Updated: June 11, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)